C. Farley

发表

Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas.

W. Greenlee, Mark D. McBriar, H. Guzik, 2006, Journal of medicinal chemistry.

Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.

W. Greenlee, M. Senior, Xiaohong Zhu, 2012, ACS medicinal chemistry letters.

Melanin-concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size.

T. Kowalski, B. Spar, C. Farley, 2004, European journal of pharmacology.

Fat intake affects adiposity, comorbidity factors, and energy metabolism of sprague-dawley rats.

C. Farley, J. Cook, M. van Heek, 2002, Obesity research.

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.

C. Farley, J. Cook, H. Davis, 2001, Diabetes.

Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice.

T. Kowalski, B. Spar, C. Farley, 2005, The Journal of endocrinology.

Evidence for distinct systemic extravasation effects of platelet activating factor, leukotrienes B4, C4, D4 and histamine in the guinea pig.

C. Farley, D. Handley, R. Deacon, 1986, Prostaglandins, leukotrienes, and medicine.

Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats

C. Farley, H. Davis, L. Hoos, 2003, British journal of pharmacology.

Discovery of a potent nicotinic Acid receptor agonist for the treatment of dyslipidemia.

Xiaohong Zhu, A. Palani, C. Farley, 2011, ACS medicinal chemistry letters.

Discovery of novel orally active ureido NPY Y5 receptor antagonists.

W. Greenlee, A. Stamford, C. Farley, 2008, Bioorganic & medicinal chemistry letters.

Meal pattern analysis of diet-induced obesity in susceptible and resistant rats.

T. Kowalski, B. Spar, C. Farley, 2003, Obesity research.

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

C. Farley, H. Davis, L. Hoos, 2000, British journal of pharmacology.

Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice.

Mark D. McBriar, H. Guzik, J. Clader, 2006, European journal of pharmacology.

Biaryl ureas as potent and orally efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity.

William J Greenlee, Anandan Palani, Brian Hawes, 2005, Journal of medicinal chemistry.

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

C. Farley, H. Davis, L. Hoos, 2001, British journal of pharmacology.

Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).

J. Lachowicz, C. Farley, Zhiwei Yang, 2013, Bioorganic & medicinal chemistry letters.

The novel cholesterol absorption inhibitor, ezetimibe, selectively inhibits the intestinal absorption of free cholesterol in the presence and absence of exocrine pancreatic function

C. Farley, H. Davis, L. Hoos, 2000 .